Apellis Pharmaceuticals (APLS) Competitors $27.57 -0.48 (-1.71%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$27.57 +0.00 (+0.00%) As of 08/29/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. VTRS, RDY, ASND, QGEN, MRNA, BBIO, ELAN, VRNA, ROIV, and GRFSShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S QIAGEN Moderna BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Apellis Pharmaceuticals (NASDAQ:APLS) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Which has preferable earnings & valuation, APLS or VTRS? Apellis Pharmaceuticals has higher earnings, but lower revenue than Viatris. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$781.37M4.46-$197.88M-$1.82-15.15Viatris$14.74B0.83-$634.20M-$2.90-3.64 Do analysts prefer APLS or VTRS? Apellis Pharmaceuticals currently has a consensus target price of $34.12, suggesting a potential upside of 23.75%. Viatris has a consensus target price of $10.40, suggesting a potential downside of 1.42%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Apellis Pharmaceuticals is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Is APLS or VTRS more profitable? Viatris has a net margin of -24.57% compared to Apellis Pharmaceuticals' net margin of -30.24%. Viatris' return on equity of 16.54% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-30.24% -116.09% -26.72% Viatris -24.57%16.54%7.06% Does the media refer more to APLS or VTRS? In the previous week, Apellis Pharmaceuticals had 12 more articles in the media than Viatris. MarketBeat recorded 17 mentions for Apellis Pharmaceuticals and 5 mentions for Viatris. Apellis Pharmaceuticals' average media sentiment score of 1.20 beat Viatris' score of 0.12 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk and volatility, APLS or VTRS? Apellis Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Do institutionals and insiders hold more shares of APLS or VTRS? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryApellis Pharmaceuticals beats Viatris on 11 of the 17 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.48B$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.10%4.04%P/E Ratio-15.1520.7883.2726.59Price / Sales4.46386.79535.03111.31Price / CashN/A44.2237.4459.26Price / Book22.238.0710.556.58Net Income-$197.88M-$53.98M$3.27B$265.95M7 Day Performance-1.43%-0.88%0.40%0.17%1 Month Performance23.41%7.72%7.31%3.90%1 Year Performance-29.13%7.03%46.58%19.67% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals3.9754 of 5 stars$27.57-1.7%$34.12+23.7%-29.1%$3.48B$781.37M-15.15770News CoveragePositive NewsInsider TradeVTRSViatris1.8341 of 5 stars$10.55-0.9%$10.40-1.4%-12.7%$12.42B$14.74B-3.6432,000RDYDr. Reddy's Laboratories2.876 of 5 stars$14.46-0.4%$16.95+17.3%-15.0%$12.11B$3.81B21.9027,811News CoveragePositive NewsASNDAscendis Pharma A/S3.3509 of 5 stars$190.37-2.0%$243.36+27.8%+40.3%$11.89B$393.54M-36.891,017News CoveragePositive NewsQGENQIAGEN3.8018 of 5 stars$48.92-1.6%$49.69+1.6%+4.8%$11.06B$1.98B28.905,765Trending NewsAnalyst RevisionMRNAModerna4.514 of 5 stars$25.35-6.5%$42.88+69.2%-68.9%$10.55B$3.24B0.005,800BBIOBridgeBio Pharma4.2489 of 5 stars$47.29-3.6%$61.35+29.7%+85.9%$9.38B$221.90M0.00400News CoveragePositive NewsAnalyst ForecastELANElanco Animal Health2.7754 of 5 stars$17.80-0.6%$17.33-2.6%+18.8%$8.90B$4.48B20.709,000VRNAVerona Pharma PLC American Depositary Share2.4269 of 5 stars$105.62+0.1%$109.00+3.2%+285.4%$8.64B$221.67M-106.6930Positive NewsROIVRoivant Sciences3.1796 of 5 stars$11.64-2.3%$16.50+41.8%-2.5%$8.14B$29.05M0.00860News CoveragePositive NewsGRFSGrifols3.5521 of 5 stars$9.82-3.3%$10.30+4.9%+6.7%$6.99B$7.81B8.3923,822Positive News Related Companies and Tools Related Companies VTRS Alternatives RDY Alternatives ASND Alternatives QGEN Alternatives MRNA Alternatives BBIO Alternatives ELAN Alternatives VRNA Alternatives ROIV Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
